Charlotte, North Carolina (January 31, 2006) – BurnsAdler Pharmaceuticals, Inc. announced today that it has entered into an agreement with Sigma Tau Pharmaceuticals, Inc. to promote the company’s Matulane® (procarbazine hydrochloride) branded product in Puerto Rico and the U.S. Virgin Islands.  Matulane® is indicated for use in combination with other anticancer drugs for the treatment of certain cancers.  The product was marketed globally by Roche before being acquired by Sigma-Tau. 

Bryan Somerville, Executive Vice President of BurnsAdler remarked, “We are very pleased to expand our ongoing relationship with Sigma-Tau to include the promotion of Matulane® in Puerto Rico and the U.S. Virgin Islands.  During the past 12 months, our sales team has reintroduced the product throughout the Latin American region and has established relationships with more than 20 new hospitals and oncology centers.  We will begin the process of establishing the Matulane® brand in Puerto Rico and look forward to equally impressive results there as well.”

Gregg Lapointe, Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc., emphasized the importance of the alliance with BurnsAdler.  “As a company specializing in drugs for rare diseases, one of our key goals is to ensure that our products are made available to all patients.  Through this distribution agreement with BurnsAdler, we are able to ensure that Matulane® continues to be available to all patients in Puerto Rico and the USVI, and that adequate resources exist in these regions to provide appropriate medical education and support to doctors interested in prescribing Matulane® for their patients.”